University of Queensland (UQ) scientists will accelerate research into cures for life-threatening genetic diseases from a Brisbane-based node of the new Medical Research Council Centre of Research Excellence for Mitochondrial Genome Therapeutics. Associate Professor Seth Cheetham from UQ’s Australian Institute for Bioengineering and Nanotechnology and Chief Investigator of… Read More
Australia’s Therapeutic Goods Administration (TGA) has approved a first-in-human trial of a T-cell therapy in multiple myeloma. The therapy, developed by HaemaLogiX in collaboration with the Peter MacCallum Cancer Centre (Peter Mac), is a KMA.CAR T-cell immunotherapy. The novel autologous CAR-T cell therapy targets Kappa Myeloma Antigen (KMA), a receptor… Read More
A potential treatment for heart attack and stroke derived from spider venom has been administered to the first participants in clinical trial. A team of researchers from the University of Queensland, Australia published preclinical analysis showing the protein Hi1a could treat heart attack and stroke patients. The… Read More
Researchers have captured the first-ever high-resolution images of yellow fever virus (YFV), which could pave the way for vaccine design. Scientists at the University of Queensland, Australia, revealed structural differences between the vaccine strain (YFV-17D) and the virulent, disease-causing strains of the virus. Researchers combined yellow fever’s structural… Read More
An experimental cancer treatment developed by researchers at the Melanoma Institute Australia paves the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne. It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of… Read More
Researchers from Flinders University and University of South Australia have unveiled a promising new strategy that could be used to treat the most aggressive forms of prostate cancer. This study, published in British Journal of Cancer, explores the role of a novel drug, CDKI-73, to tackle… Read More
New research by Australian biotechnology company Magellan Stem Cells has demonstrated potential therapeutic benefits of a stem cell therapy for osteoarthritis. The Phase I/II clinical trial assessed the safety and efficacy of MAG200, Magellan Stem Cells’ off-the-shelf allogeneic (donor) stem cell therapy for osteoarthritis of the… Read More
Australian researchers have analysed how an antidiabetic treatment could help control the growth of tumours, potentially paving the way for the design of better cancer treatments. The new study investigated what happens when metformin, a type 2 diabetes medication, is used to treat colorectal cancer cells,… Read More
The Phase IIa ACCENT trial has launched to explore the activity of focal adhesion kinase (FAK) inhibitor narmafotinib in combination with standard-of-care chemotherapy in advanced pancreatic cancer patients. In November 2023, Amplia Therapeutics announced completion of the Phase Ib stage of the ACCENT trial where ascending… Read More
Osteoarthritis may be treatable and reversible, according to a new University of Adelaide study. The researchers have discovered a novel population of stem cells – marked by the Gremlin 1 gene – responsible for the progression of osteoarthritis. Treatment with fibroblast growth factor 18… Read More
As demand for mRNA continues to surge, two new facilities have been launched to boost production in Australia and the US. Work is underway at The University of Queensland’s (UQ) BASE facility which has become Australia’s leading provider of mRNA for research and pilot studies since… Read More
Emeritus Professor Ian Frazer, University of Queensland and Director of Microba, has been announced as the Millis Oration keynote speaker for AusBiotech 2023. The title of his presentation will be ‘Navigating the future: Predictions and potential of Australian biotechnology’. He will share his assessment… Read More
